

Page 25
Notes:
conferenceseries
.com
Volume 6, Issue 8 (Suppl)
J Biotechnol Biomater
ISSN: 2155-952X JBTBM, an open access journal
Bio America 2016
November 28-30, 2016
November 28-30, 2016 San Francisco, USA
13
th
Biotechnology Congress
Antibody engineering from hybridoma-derived monoclonal antibodies
Lmar Babrak
United States Department of Agriculture-Agricultural Research Service, USA
A
ntibody engineering requires the identification of antigen binding domains (variable regions; VRs) unique to each antibody.
This determination can be achieved by sequence analysis of the antibody transcript obtained from the hybridoma as each
clonal hybridoma cell line produces in principle a single antigen specific monoclonal antibody (MAb). However, the polyploidy
nature of hybridoma cells often results in the added expression of aberrant immunoglobulin-like transcripts or even production of
nondescript antibodies. The occurrence of these transcripts confounds identification of the VRs of immunoglobulin heavy and light
chains that correspond to the antigen specific antibody. It is the VRs that define the unique antigen binding properties and proper
sequence identification is essential for functional performance of a recombinant engineered antibody. To address this problem, we
have identified and complied a database of aberrant Ig-like transcripts found in myeloma cell lines (SP2/0-Ag14 and P3X62A8U.1)
frequently used in the generation of hybridomas and developed a PCR-based method for the selective amplification of heavy and light
chain VRs from a given antigen specific immunoglobulin isotype combined withmolecular cloning and DNA based sequence analysis.
These methods should increase the certainty regarding the VR sequence structure when evaluating the functional performance of
a recombinant antibody. This work serves to facilitate antibody engineering applications with broad interest to biotechnology and
pharmaceutical industries.
Biography
Lmar Babrak is currently a Post-doctoral Research Scientist in the laboratory of Dr. Robert Hnasko at the Agricultural Research Service located in Albany, CA. Her
research has focused on the development of immunoassays used for the detection of disease causing pathogens, toxins and other agricultural contaminants. She
has completed her PhD in Microbiology in 2015 from Oregon State University.
Lmar.Babrak@ars.usda.govLmar Babrak, J Biotechnol Biomater 2016, 6:8(Suppl)
http://dx.doi.org/10.4172/2155-952X.C1.067